Geoff Hale
Sir William Dunn School of Pathology
University of Oxford
UK
Name/email consistency: high
- Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Hale, G., Rebello, P., Brettman, L.R., Fegan, C., Kennedy, B., Kimby, E., Leach, M., Lundin, J., Mellstedt, H., Moreton, P., Rawstron, A.C., Waldmann, H., Osterborg, A., Hillmen, P. Blood (2004)
- Design and manufacture of monoclonal antibodies for radioimmunotherapy. Hale, G., Berrie, E., Bird, P. Quarterly J. Nuclear Medicine Molecular Imaging : Official Publication Italian Association Nuclear Medicine (aimn) [and] International Association Radiopharmacology (iar), [and] Section Society Radiopharmaceut... (2004)
- Alemtuzumab in stem cell transplantation. Hale, G. Med. Oncol. (2002)
- Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Hale, G., Zhang, M.J., Bunjes, D., Prentice, H.G., Spence, D., Horowitz, M.M., Barrett, A.J., Waldmann, H. Blood (1998)